This recombinant monoclonal antibody is designed as a research-grade biosimilar to Gotistobart, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in autoimmune diseases and plays a significant role in tumor immune evasion, making it a valuable target for immunological research.
Gotistobart is a therapeutic monoclonal antibody developed to modulate CTLA4 activity in immune-related conditions. This biosimilar antibody provides researchers with a reliable tool for investigating CTLA4 biology, exploring immune checkpoint mechanisms, and studying T-cell regulation in various disease models. It supports investigations into autoimmunity, transplantation immunology, and cancer immunotherapy research, enabling detailed analysis of CTLA4's role in immune modulation.
Email: support@cusabio.com
Distributors Worldwide